SEC Form 4 · accession 0002076327-26-000006
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roland Wilhelm Kolbeck
Officer — Chief Scientific Officer
Period of report
Aug 1, 2026
Accepted (ET)
Aug 4, 2026 · 5:03 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 1, 2026 | M | 36,375 | — | A | 36,375 | D | |
| Common Stock | Aug 1, 2026 | F | 12,385 | $5.20 | D | 23,990 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Aug 1, 2026 | M | 36,375 | D | — | — | Common Stock | 36,375 | 109,125 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- F2The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
- F3The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.